Welcome to our dedicated page for Steris news (Ticker: STE), a resource for investors and traders seeking the latest updates and insights on Steris stock.
STERIS plc provides healthcare and life sciences products and services that support patient care, with an emphasis on infection prevention. Its recurring news includes financial results and outlook updates for continuing operations, quarterly dividend actions, conference-call announcements, and board or executive governance changes.
The company’s business updates center on sterilization services, Applied Sterilization Technologies, sterilizers, washer-disinfectors, and decontamination equipment and supplies used by care providers and biopharma manufacturing sites. Corporate announcements also address capital spending, cash flow expectations, and shareholder distribution information.
STERIS plc (NYSE: STE) has announced its participation in the Morgan Stanley Healthcare Conference on September 4, 2024, in New York City. Dan Carestio, President and CEO of STERIS, will present at 1:50 p.m. Eastern Time.
The presentation will be simultaneously webcast and available for replay on STERIS's investor relations website at www.steris-ir.com. STERIS is a leading global provider of products and services supporting patient care, with a focus on infection prevention.
The company's mission is to help customers create a healthier and safer world by offering innovative healthcare and life sciences solutions globally. For further information, investors can contact Julie Winter, Vice President of Investor Relations and Corporate Communications.
STERIS plc (NYSE: STE) reported strong financial results for Q1 fiscal 2025. Total revenue from continuing operations increased 8% to $1.3 billion, with constant currency organic revenue growing 6%. As reported EPS from continuing operations rose to $1.41, while adjusted EPS increased to $2.03.
Healthcare revenue grew 10% to $901.2 million, driven by 23% growth in consumables and 14% in services. Applied Sterilization Technologies revenue increased 7% to $249.8 million. Life Sciences revenue decreased 2% to $128.5 million due to a divestiture.
The company reiterated its fiscal 2025 outlook, expecting 6.5-7.5% revenue growth and adjusted EPS of $9.05-$9.25. STERIS remains confident in delivering on its full-year guidance.
STERIS plc (NYSE: STE) has announced a 5.6% increase in its quarterly dividend to $0.57 per share, marking the company's 19th consecutive year of dividend growth. The dividend will be payable on September 20, 2024, to shareholders of record as of September 5, 2024. This represents a $0.05 increase from the previous dividend.
STERIS, a global leader in infection prevention products and services for healthcare and life sciences, continues to demonstrate its commitment to shareholder value through consistent dividend growth. The company's focus on creating a healthier and safer world through innovative solutions underscores its strong market position and financial stability.
STERIS plc (NYSE: STE) has announced it will host a conference call on August 7, 2024, at 9:00 a.m. ET to discuss its fiscal 2025 first quarter financial results. The call can be accessed via www.steris-ir.com or by phone. A press release detailing the financial results will be issued after the U.S. market closes on August 6, 2024. For those unable to attend the live call, a replay will be available from 12:00 p.m. ET on August 7, 2024, accessible through the company website or by phone using the access code 5644736. This announcement provides investors and analysts an opportunity to gain insights into STERIS's recent financial performance and future outlook.
An affiliate of Peak Rock Capital has completed the acquisition of HuFriedyGroup, the dental segment of STERIS plc (NYSE: STE). HuFriedyGroup, founded in 1908, is a global leader in dental instruments, infection prevention products, and instrument management systems. The company serves customers in approximately 100 countries and employs around 1,500 people across more than 20 global facilities. Peak Rock Capital sees this acquisition as a significant investment opportunity, aiming to drive new product innovation and organic growth. The firm also plans to support complementary acquisitions to expand the product and brand portfolio.
STERIS plc (NYSE: STE) announced financial results for its fiscal 2024 fourth quarter and full year, with total revenue up 12% to $5.5 billion. U.S. GAAP earnings per diluted share were $3.81, adjusted earnings per diluted share increased to $8.83. The company reported a targeted restructuring plan. Fourth quarter revenue increased 10% to $1.5 billion. Healthcare segment outperformed, with revenue growth primarily in the United States. Fiscal 2025 outlook includes mid-to-high single digit revenue growth and double-digit earnings growth.
STERIS plc (NYSE: STE) declared a quarterly interim dividend of $0.52 per share, payable on June 26, 2024. The Company focuses on infection prevention in healthcare and offers healthcare, life sciences, and dental products globally.
Summary not available.
Summary not available.
Summary not available.